ArticleMolecules (Basel, Switzerland)2015
Separation and Identification of Four New Compounds with Antibacterial Activity from Portulaca oleracea L.
Article in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A Randomized Comparative Study of Luteolin-Based Herbal Unani FormulationsCurrent pharmaceutical design · 2025Trial
- Resilience of Portulaca plants to environmental stresses and the economic potential of their bioactive compounds.Planta · 2025Review
- Wild grown Portulaca oleracea as a novel magnetite based carrier with in vitro antioxidant and cytotoxicity potential.Scientific reports · 2025Article
- (Nutrients · 2024Article
- Unveiling antioxidant capacity of standardized chitosan-tripolyphosphate microcapsules containing polyphenol-rich extract ofHeliyon · 2024Article
- HM-chromanone alleviates hyperglycemia and inflammation in mice with endotoxin-induced insulin resistance.Toxicology research · 2023Article
- Assessment of the Volatile Profiles and Identification of Differentiating Aromas of Wild Undervalued Plants.Frontiers in nutrition · 2022Article
- Article
- Review
- Bioactive Phytochemicals from Mulberry: Potential Anti-Inflammatory Effects in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages.International journal of molecular sciences · 2021Article
- Potential antibacterial and antifungal activities of novel sulfamidophosphonate derivatives bearing the quinoline or quinolone moiety.Archiv der Pharmazie · 2021Article
- Article
- Dietary purslane (Portulaca oleracea L.) promotes the growth performance of broilers by modulation of gut microbiota.AMB Express · 2021Article
- Component Composition and Antimicrobial Activity of COTheScientificWorldJournal · 2021Article
- Antioxidant Potential of Artemisia capillaris, Portulaca oleracea, and Prunella vulgaris Extracts for Biofabrication of Gold Nanoparticles and Cytotoxicity Assessment.Nanoscale research letters · 2018Article
- The Antitumor Constituents from Hedyotis Diffusa Willd.Molecules (Basel, Switzerland) · 2017Article
- Design, Synthesis and Antibacterial Evaluation of Some New 2-Phenyl-quinoline-4-carboxylic Acid Derivatives.Molecules (Basel, Switzerland) · 2016Article
- Portulacerebroside A inhibits adhesion, migration, and invasion of human leukemia HL60 cells and U937 cells through the regulation of p38/JNK signaling pathway.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Portulaca oleracea L. (P. oleracea) has been used to treat bacillary dysentery for thousands of years in China. Pharmacology studies on P. oleracea have also showed its significant antibacterial effects on the enteropathogenic bacteria, which might reveal the treatment of P. oleracea in cases of bacillary dysentery to some extent. To date, however, the therapeutic basis of P. oleracea treating on bacillary dysentery remains unknown. We determined the antibacterial effective fraction of P. oleracea in a previous study. The current study, which is based on our previous study, was first designed to isolate, identify and screen antibacterial active constituents from P. oleracea. As a result, four new compounds (1-4), portulacerebroside B (1), portulacerebroside C (2), portulacerebroside D (3) and portulaceramide A (4) along with five known compounds (5-9) were isolated, and structures were established by their physico-chemical constants and spectroscopic analysis. The antibacterial activities against common enteropathogenic bacteria were evaluated for all compounds and the new compounds 1-4 showed significant antibacterial effect on enteropathogenic bacteria in vitro, which might contribute to revealing the treatment of P. oleracea in cases of bacillary dysentery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.